Oxybee

Country: European Union

Language: Estonian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
13-03-2018
Summary of Product characteristics Summary of Product characteristics (SPC)
13-03-2018
Public Assessment Report Public Assessment Report (PAR)
13-03-2018

Active ingredient:

oksaalhape dihüdraat

Available from:

Dany Bienenwohl GmbH

ATC code:

QP53AG03

INN (International Name):

oxalic acid dehydrate

Therapeutic group:

Mesilased

Therapeutic area:

Nahaparasiidi paikseks kasutamiseks, sh. insektitsiidid

Therapeutic indications:

Ravi varroosis (Varroa destructor) mesilaste (Apis mellifera) haudme-tasuta kolooniad.

Authorization status:

Volitatud

Authorization date:

2018-02-01

Patient Information leaflet

                                19
B.
PAKENDI INFOLEHT
20
PAKENDI INFOLEHT
OXYBEE
39,4 mg/ml
MESITARU DISPERSIOONI PULBER JA LAHUS MEEMESILASTELE
1.
MÜÜGILOA HOIDJA NING, KUI NEED EI KATTU, RAVIMIPARTII
KASUTAMISEKS VABASTAMISE EEST VASTUTAVA TOOTMISLOA HOIDJA
NIMI JA AADRESS
Müügiloa hoidja
:
Dany Bienenwohl GmbH
Geyerspergerstr. 27
80689 Munich
Saksamaa
Ravimipartii kasutamiseks vabastamise eest vastutav tootja
:
Wirtschaftsgenossenschaft deutscher Tierärzte (WDT) eG
Siemensstraße 14
30827 Garbsen
Saksamaa
2.
VETERINAARRAVIMI NIMETUS
Oxybee 39,4 mg/ml mesitaru dispersiooni pulber ja lahus meemesilastele
3.
TOIMEAINETE JA ABIAINETE SISALDUS
Üks
375 G LAHUSEPUDEL
sisaldab
TOIMEAINE
Oksaalhappe dihüdraat 17,5 g (vastab 12,5 g oksaalhappele)
Selge ja värvitu lahus.
Üks
750 G LAHUSEPUDEL
sisaldab
TOIMEAINE
Oksaalhappe dihüdraat 35,0 g (vastab 25,0 g oksaalhappele)
Selge ja värvitu lahus.
Üks
125 G PULBRIKOTIKE
sisaldab
ABIAINED
Sahharoos 125 g
1 ml
SEGATUD MESITARU DISPERSIOONI
sisaldab
TOIMEAINE
Oksaalhappe dihüdraat 39,4 mg (vastab 28,1 mg oksaalhappele)
Läbipaistev kuni kergelt hägune värvitu dispersioon.
4.
NÄIDUSTUS(ED)
Meemesilaste (
_Apis mellifera)_
varroatoosi (
_Varroa destructor) _
ravi haudeta peredes.
21
5.
VASTUNÄIDUSTUSED
Ei ole.
6.
KÕRVALTOIMED
Kliinilistes uuringutes täheldati väga sageli mesilaste suremuse
suurenemist. See ei mõjutanud pere
pikaajalist arengut.
Kõrvaltoimete esinemissagedus on defineeritud järgnevalt:
- väga sage (kõrvaltoime(d) ilmnes(id) rohkem kui 1-l perel 10st
ravitud perest)
- sage (rohkem kui 1-l, kuid vähem kui 10-l perel 100st ravitud
perest)
- aeg-ajalt (rohkem kui 1-l, kuid vähem kui 10-l perel 1000st ravitud
perest)
- harv (rohkem kui 1-l, kuid vähem kui 10-l perel 10 000st ravitud
perest)
- väga harv (vähem kui 1-l perel 10 000st ravitud perest, kaasa
arvatud üksikjuhud)
7.
SIHTLIIGID
Meemesilased (
_Apis mellifera)_
8.
ANNUSTAMINE LOOMALIIGITI, MANUSTAMISVIIS(ID) JA -MEETOD
Kasutamiseks mesitarus.
Annus
Maksimumannus on 5...6 ml mesitaru valmisdispersiooni mesilaste

                                
                                Read the complete document

Summary of Product characteristics

                                1
I LISA
RAVIMI OMADUSTE KOKKUVÕTE
2
1.
VETERINAARRAVIMI NIMETUS
Oxybee 39,4 mg/ml mesitaru dispersiooni pulber ja lahus meemesilastele
2.
KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS
Üks
375 G LAHUSEPUDEL
sisaldab
TOIMEAINE
Oksaalhappe dihüdraat 17,5 g (vastab 12,5 g oksaalhappele)
ABIAINED
Abiainete täielik loetelu on esitatud lõigus 6.1
Üks
750 G LAHUSEPUDEL
sisaldab
TOIMEAINE
Oksaalhappe dihüdraat 35,0 g (vastab 25,0 g oksaalhappele)
ABIAINED
Abiainete täielik loetelu on esitatud lõigus 6.1
Üks
125 G PULBRIKOTIKE
sisaldab
ABIAINED
Sahharoos 125 g
Abiainete täielik loetelu on esitatud lõigus 6.1
1 ml valmis
SEGATUD MESITARU DISPERSIOONI
sisaldab
TOIMEAINE
Oksaalhappe dihüdraat 39,4 mg (vastab 28,1 mg oksaalhappele)
ABIAINED
Abiainete täielik loetelu on esitatud lõigus 6.1
3.
RAVIMVORM
Mesitaru dispersiooni pulber ja lahus.
Mesitaru dispersiooni lahus (toimeainet sisaldav pudel):
selge ja värvitu lahus.
Mesitaru dispersiooni pulber (kotike):
valge kristalne pulber.
4.
KLIINILISED ANDMED
4.1
SIHTLIIGID
Meemesilased (
_Apis mellifera) _
_ _
4.2
NÄIDUSTUSED, MÄÄRATES KINDLAKS VASTAVAD SIHTLIIGID
Meemesilaste (
_Apis mellifera)_
varroatoosi (
_Varroa destructor) _
ravi haudeta peredes.
3
4.3
VASTUNÄIDUSTUSED
Ei ole.
4.4
ERIHOIATUSED IGA SIHTLIIGI KOHTA
Oxybeed tohib haudeta peredes kasutada ainult üks kord.
Seda veterinaarravimit tohib kasutada ainult integreeritud varroatoosi
tõrjeprogrammi raames koos
langenud lestade regulaarse jälgimisega. Võimaluse korral kasutage
seda veterinaarravimit
vaheldumisi varroatoosi raviks heaks kiidetud muu toimemehhanismiga
veterinaarravimiga, et
vähendada resistentsuse teket varroalestadel.
4.5
ERIHOIATUSED
Ettevaatusabinõud kasutamisel loomadel
Ärge ületage soovitatavat annust ega manustage seda
veterinaarravimit rohkem kui üks kord.
Mesilased ei pruugi korduvat ravi hästi taluda. Kui ühe pere
töömesilasi ravitakse rohkem kui üks
kord, võib see mesilasi kahjustada ja põhjustada pere tugevuse
vähenemist.
Korduvnakatumise vältimiseks peab samas mes
                                
                                Read the complete document

Similar products

Active ingredient oksaalhape dihüdraat

oksaalhape dihüdraat

ATC code QP53AG03

QP53AG03

Marketed by Dany Bienenwohl GmbH

Dany Bienenwohl GmbH

INN (International Name) oxalic acid dehydrate

oxalic acid dehydrate

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 13-03-2018
Summary of Product characteristics Summary of Product characteristics Bulgarian 13-03-2018
Public Assessment Report Public Assessment Report Bulgarian 13-03-2018
Patient Information leaflet Patient Information leaflet Spanish 13-03-2018
Summary of Product characteristics Summary of Product characteristics Spanish 13-03-2018
Public Assessment Report Public Assessment Report Spanish 13-03-2018
Patient Information leaflet Patient Information leaflet Czech 13-03-2018
Summary of Product characteristics Summary of Product characteristics Czech 13-03-2018
Public Assessment Report Public Assessment Report Czech 13-03-2018
Patient Information leaflet Patient Information leaflet Danish 13-03-2018
Summary of Product characteristics Summary of Product characteristics Danish 13-03-2018
Public Assessment Report Public Assessment Report Danish 13-03-2018
Patient Information leaflet Patient Information leaflet German 13-03-2018
Summary of Product characteristics Summary of Product characteristics German 13-03-2018
Public Assessment Report Public Assessment Report German 13-03-2018
Patient Information leaflet Patient Information leaflet Greek 13-03-2018
Summary of Product characteristics Summary of Product characteristics Greek 13-03-2018
Public Assessment Report Public Assessment Report Greek 13-03-2018
Patient Information leaflet Patient Information leaflet English 13-03-2018
Summary of Product characteristics Summary of Product characteristics English 13-03-2018
Public Assessment Report Public Assessment Report English 13-03-2018
Patient Information leaflet Patient Information leaflet French 13-03-2018
Summary of Product characteristics Summary of Product characteristics French 13-03-2018
Public Assessment Report Public Assessment Report French 13-03-2018
Patient Information leaflet Patient Information leaflet Italian 13-03-2018
Summary of Product characteristics Summary of Product characteristics Italian 13-03-2018
Public Assessment Report Public Assessment Report Italian 13-03-2018
Patient Information leaflet Patient Information leaflet Latvian 13-03-2018
Summary of Product characteristics Summary of Product characteristics Latvian 13-03-2018
Public Assessment Report Public Assessment Report Latvian 13-03-2018
Patient Information leaflet Patient Information leaflet Lithuanian 13-03-2018
Summary of Product characteristics Summary of Product characteristics Lithuanian 13-03-2018
Public Assessment Report Public Assessment Report Lithuanian 13-03-2018
Patient Information leaflet Patient Information leaflet Hungarian 13-03-2018
Summary of Product characteristics Summary of Product characteristics Hungarian 13-03-2018
Public Assessment Report Public Assessment Report Hungarian 13-03-2018
Patient Information leaflet Patient Information leaflet Maltese 13-03-2018
Summary of Product characteristics Summary of Product characteristics Maltese 13-03-2018
Public Assessment Report Public Assessment Report Maltese 13-03-2018
Patient Information leaflet Patient Information leaflet Dutch 13-03-2018
Summary of Product characteristics Summary of Product characteristics Dutch 13-03-2018
Public Assessment Report Public Assessment Report Dutch 13-03-2018
Patient Information leaflet Patient Information leaflet Polish 13-03-2018
Summary of Product characteristics Summary of Product characteristics Polish 13-03-2018
Public Assessment Report Public Assessment Report Polish 13-03-2018
Patient Information leaflet Patient Information leaflet Portuguese 13-03-2018
Summary of Product characteristics Summary of Product characteristics Portuguese 13-03-2018
Public Assessment Report Public Assessment Report Portuguese 13-03-2018
Patient Information leaflet Patient Information leaflet Romanian 13-03-2018
Summary of Product characteristics Summary of Product characteristics Romanian 13-03-2018
Public Assessment Report Public Assessment Report Romanian 13-03-2018
Patient Information leaflet Patient Information leaflet Slovak 13-03-2018
Summary of Product characteristics Summary of Product characteristics Slovak 13-03-2018
Public Assessment Report Public Assessment Report Slovak 13-03-2018
Patient Information leaflet Patient Information leaflet Slovenian 13-03-2018
Summary of Product characteristics Summary of Product characteristics Slovenian 13-03-2018
Public Assessment Report Public Assessment Report Slovenian 13-03-2018
Patient Information leaflet Patient Information leaflet Finnish 13-03-2018
Summary of Product characteristics Summary of Product characteristics Finnish 13-03-2018
Public Assessment Report Public Assessment Report Finnish 13-03-2018
Patient Information leaflet Patient Information leaflet Swedish 13-03-2018
Summary of Product characteristics Summary of Product characteristics Swedish 13-03-2018
Public Assessment Report Public Assessment Report Swedish 13-03-2018
Patient Information leaflet Patient Information leaflet Norwegian 13-03-2018
Summary of Product characteristics Summary of Product characteristics Norwegian 13-03-2018
Patient Information leaflet Patient Information leaflet Icelandic 13-03-2018
Summary of Product characteristics Summary of Product characteristics Icelandic 13-03-2018
Patient Information leaflet Patient Information leaflet Croatian 13-03-2018
Summary of Product characteristics Summary of Product characteristics Croatian 13-03-2018
Public Assessment Report Public Assessment Report Croatian 13-03-2018

Search alerts related to this product

Alerts Oxybee oksaalhape dihüdraat oxalic acid dehydrate

Oxybee oksaalhape dihüdraat oxalic acid dehydrate

View documents history

Documents history Documents history

Oxybee